MASP1 and COVID-19: In the case of COVID-19, blocking LP through a MASP inhibitor may suffice to inhibit hyperinflammation and microcoagulation events, because (1) this pathway appears to be the first to get activated in contact with the virus, (2) MASPs activate key arms of the coagulation cascade and (3) MASP2 can recognize SARS-Cov-2 viral N protein.